4-Hydroxy Nebivolol, a primary metabolite of Nebivolol, results from the enzymatic hydroxylation of Nebivolol by the cytochrome P450 (CYP) isoform CYP2D6.
Dexnebivolol ( R67138) is an antagonist of the ß-adrenergic receptor and is an enantiomer of Nebivolol. Nebivolol is a β1 receptor blocker with nitric oxide enhancing vasodilation effect.